US Representative

Earl Carter 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 6)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2630

Introduced
4/13/23  
Safe Step Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2666

Introduced
4/18/23  
Refer
4/18/23  
Refer
5/15/23  
Medicaid VBPs for Patients Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2673

Introduced
4/18/23  
American Innovation and R&D Competitiveness Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2679

Introduced
4/18/23  
Pharmacy Benefits Manager Accountability Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2700

Introduced
4/19/23  
Employee Rights Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2743

Introduced
4/20/23  
Fair Access to Banking Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2745

Introduced
4/20/23  
HACT Act Homeland And Cyber Threat Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB277

Introduced
1/11/23  
Refer
1/11/23  
Report Pass
5/24/23  
Regulations from the Executive in Need of Scrutiny Act of 2023 This bill revises provisions relating to congressional review of agency rulemaking. Specifically, the bill establishes a congressional approval process for a major rule. A major rule may only take effect if Congress approves of the rule. A major rule is a rule that has resulted in or is likely to result in (1) an annual effect on the economy of $100 million or more; (2) a major increase in costs or prices for consumers, individual industries, government agencies, or geographic regions; or (3) significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S.-based enterprises to compete with foreign-based enterprises. The bill generally preserves the current congressional review process for a nonmajor rule.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2808

Introduced
4/24/23  
Arnold Daniel Palmer Commemorative Coin Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2811

Introduced
4/25/23  
Refer
4/25/23  
Refer
4/26/23  
Refer
4/26/23  
Refer
4/26/23  
Refer
4/26/23  
Refer
4/26/23  
Water Quality Certification and Energy Project Improvement Act of 2023 TAPP American Resources Act Transparency, Accountability, Permitting, and Production of American Resources Act Regulations from the Executive in Need of Scrutiny Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2826

Introduced
4/25/23  
Save Local Business Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2827

Introduced
4/25/23  
Partner with Korea Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2849

Introduced
4/25/23  
Rare Earth Magnet Manufacturing Production Tax Credit Act of 2023

Primary Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2707

Introduced
4/19/23  
MADE in America Act Manufacturing API, Drugs, and Excipients in America Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB279

Introduced
1/11/23  
Refer
1/11/23  
Pharmacist Conscience Protection Act This bill prohibits the federal government and federally funded entities from discriminating or otherwise taking adverse action against a pharmacist, pharmacy owner, or pharmacy technician who declines to store, fill prescriptions for, or make referrals for drugs that cause abortions (or that the individual provider believes in good faith cause abortions). Individuals or the Department of Justice may bring civil actions for violations of this bill.